Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier.
AUTOR(ES)
Polt, R
RESUMO
Most peptides have not proved useful as neuroactive drugs because they are blocked by the blood-brain barrier and do not reach their receptors within the brain. Intraperitoneally administered L-serinyl beta-D-glucoside analogues of [Met5]enkephalin (glycopeptides) have been shown to be transported across the blood-brain barrier to bind with targeted mu- and delta-opioid receptors in the mouse brain. The opioid nature of the binding has been demonstrated with intracerebroventricularly administered naloxone. Paradoxically, glucosylation decreases the lipophilicity of the peptides while promoting transport across the lipophilic endothelial layer. It is suggested that glucose transporter GLUT-1 is responsible for the transport of the peptide message. Profound and long-lasting analgesia has been observed in mice (tail-flick and hot-plate assays) with two of the glycopeptide analogues when administered intraperitoneally.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=44349Documentos Relacionados
- Rational approaches to breaching the blood-brain barrier.
- Transcytotic pathway for blood-borne protein through the blood-brain barrier.
- Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation.
- Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier.
- Enhancement of ketoconazole penetration across the blood-brain barrier of mice by dimethyl sulfoxide.